ALX Oncology Holdings Inc. (ALXO)
| Market Cap | 205.88M +759.3% |
| Revenue (ttm) | n/a |
| Net Income | -88.87M |
| EPS | -1.34 |
| Shares Out | 134.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197,451 |
| Open | 1.430 |
| Previous Close | 1.460 |
| Day's Range | 1.430 - 1.535 |
| 52-Week Range | 0.404 - 2.660 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 4.60 (+200.65%) |
| Earnings Date | May 8, 2026 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 200.65% from the latest price.
News
ALX Oncology Holdings Transcript: AGM 2026
Directors and management were introduced, and all voting proposals—including director elections, executive compensation, and auditor ratification—were approved. Clinical programs evorpacept and ALX2004 showed progress, with key data readouts expected in the next 12-18 months.
ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two clinical programs are advancing: evorpacept, showing strong efficacy in HER2-positive cancers, and ALX2004, a differentiated EGFR ADC with promising safety and dose escalation. ASPEN-09 phase II will refine CD47 biomarker strategy, with key data and regulatory discussions expected next year.
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies ...
ALX Oncology Holdings Earnings Call Transcript: Q1 2026
New data show evorpacept plus zanidatamab delivers high response rates and durable benefit in heavily pre-treated HER2-positive breast cancer, especially in CD47-high patients. ASPEN-09 and ALX2004 trials are progressing on schedule, with strong financial backing and leadership.
ALX Oncology Holdings Earnings release: Q1 2026
ALX Oncology Holdings released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
ALX Oncology Holdings Slides: Q1 2026
ALX Oncology Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
ALX Oncology Holdings Quarterly report: Q1 2026
ALX Oncology Holdings has published its Q1 2026 quarterly earnings report on May 8, 2026.
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable resp...
ALX Oncology evorpacept combination data presented at ESMO congress
ALX Oncology (ALXO) announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceu...
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasda...
ALX Oncology Holdings Proxy statement: Proxy filing
ALX Oncology Holdings filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapie...
ALX Oncology appoints Jeff Knight as chief development, operating officer
ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crin...
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
ALX Oncology initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of ALX Oncology (ALXO) with an Overweight rating and $5 price target The firm thinks the near-term update for the evorpacept plus zanidatamab combo in metastatic…
ALX Oncology price target raised to $4 from $2 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on ALX Oncology (ALXO) to $4 from $2 and keeps a Buy rating on the shares. The firm says the…
ALX Oncology initiated with a Buy at UBS
UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II…
ALX Oncology Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Two novel oncology programs are advancing, with evorpacept showing strong efficacy and safety in HER2-positive cancers and ALX2004 progressing in dose escalation. CD47 overexpression is now a key biomarker, and recent financing supports pivotal milestones through 2028.
ALX Oncology Holdings Slides: Corporate presentation
ALX Oncology Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
ALX Oncology Holdings Earnings Call Transcript: Q4 2025
Strong clinical progress in 2025 with Evorpacept and ALX2004, highlighted by robust efficacy in CD47-high cancer patients and a $150M financing extending cash runway through H1 2028. Key data readouts are expected in 2026–2027.
ALX Oncology Holdings Annual report: Q4 2025
ALX Oncology Holdings has published its Q4 2025 annual report on February 27, 2026.
ALX Oncology Holdings Earnings release: Q4 2025
ALX Oncology Holdings released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
ALX Oncology Holdings Slides: Q4 2025
ALX Oncology Holdings has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
ALX Oncology Holdings Annual report: Q4 2025
ALX Oncology Holdings has published its Q4 2025 annual report on February 27, 2026.